The newly identified signatures of aberrant histone PTMs, such as the targeted histone hypoacetylation and hypomethylation, may be used in the future as prognostic or predictive epigenetic markers in patients with JMML caused by PTPN11 mutation. This evidence concerns the gene PTPN11 and juvenile myelomonocytic leukemia.